Balyasny Asset Management’s Ovid Therapeutics OVID Stock Holding History

Balyasny Asset Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.3M	Buy	5,533,073 +5,208,073	+1,602%	+$9.31M	0.02%	940
2025 Q4	$530K	Sell	325,000 -300,000	-48%	-$462K	﹤0.01%	2503
2025 Q3	$813K	Buy	+625,000	New	+$542K	﹤0.01%	2206
2023 Q2	–	Sell	-24,056	Closed	-$62.1K	–	2651
2023 Q1	$62.1K	Buy	+24,056	New	+$57K	﹤0.01%	2364
2022 Q4	–	Sell	-31,938	Closed	-$59K	–	3113
2022 Q3	$59K	Buy	+31,938	New	+$66.8K	﹤0.01%	2457

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Balyasny Asset Management's OVID Position: Q1 2026 in Review

Balyasny Asset Management increased its Ovid Therapeutics (OVID) stake by 1,602% in Q1 2026, buying an estimated $9.31M and bringing the position to 5,533,073 shares worth $12.3M. The position accounts for 0.02% of the portfolio, ranked #940.

Balyasny Asset Management first reported a position in OVID in Q3 2022 and has held it in 5 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Balyasny Asset Management held 5,533,073 shares of Ovid Therapeutics worth $12.3M as of Q1 2026.
Balyasny Asset Management bought 5,208,073 Ovid Therapeutics shares in Q1 2026, an estimated $9.31M.
Ovid Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #940 holding.
Balyasny Asset Management first reported a position in Ovid Therapeutics in Q3 2022 and has held it in 5 quarters since.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.